INTRODUCTION {#Sec1}
============

Treacher Collins--Franceschetti syndrome (TCS; TCS1 \[OMIM 154500\], TCS2 \[OMIM 613717\], TCS3 \[OMIM 248390\]) is a rare disorder of craniofacial development with an estimated incidence of 1/50,000 live births.^[@CR1]^ TCS belongs to a large group of disorders called mandibulofacial dysostosis (MFD). Features of TCS include bilateral malar and mandibular hypoplasia with associated facial features (microtia, coloboma, and downslanting palpebral fissures) and other features such as conductive deafness, cleft palate, and heart malformations. Facial features in TCS are due to abnormal neural crest cell (NCC) migration secondary to nucleolar stress, decreased ribosome biogenesis, and apoptosis.^[@CR2],[@CR3]^ Therefore, TCS belongs to the neurocristopathies and ribosomopathies, a large group of disorders.

To date, three genes are known to be involved in TCS: treacle ribosome biogenesis factor 1 (*TCOF1*; OMIM 606847),^[@CR4]^ RNA polymerase I (pol I) subunit C (*POLR1C*, OMIM 610060), and RNA pol I subunit D (*POLR1D*, OMIM 613715).^[@CR5]^ Pathogenic variants in *TCOF1* are responsible for about 80--85% of TCS cases with typical facial features, whereas *POLR1C* and *POLR1D* are involved in less than 10%.^[@CR6]^

However, despite a large number of TCS individuals with a molecular diagnosis, some remain without a known genetic anomaly. We took advantage of a large series of TCS patients without pathogenic variants in the three known genes responsible for TCS or other known MFD genes.^[@CR6]^ We performed exome sequencing to identify novel pathogenic variants and/or genes and in vivo functional studies in zebrafish to try to elucidate the underlying pathophysiological mechanisms.

MATERIALS AND METHODS {#Sec2}
=====================

Patients {#Sec3}
--------

From a large cohort of 146 patients with TCS previously reported,^[@CR6]^ we identified 6 without a pathogenic variant or causative copy-number variation in the genes involved in MFD. To try to identify the precise molecular defect in these 6 TCS patients without a molecular diagnosis (6/146, 4%), we performed trio exome sequencing in 4 of the 6 patients and their parents. After identifying a candidate gene in 2 of the 4 patients (2/146, 1.3%) and in 1 patient's mother, we then gathered 3 additional patients via international collaboration (using GeneMatcher^[@CR7]^ for 1 patient). Clinical data are summarized in Table [1](#Tab1){ref-type="table"}.Table 1Molecular and clinical data for patients with TCSPatient 1Patient 2Patient 3Patient 4Patient 5Patient 6Molecular anomalyp.(Arg1003Cys) (exon 15)p.(Ser682Arg) (exon 12)p.(Ser682Arg) (exon 12)p.(Arg1003Cys) (exon 15)p.(Arg1003Ser) (exon 15)p.(Arg1003Cys) (exon 15)gDNA position (GRCh38/hg38)chr2:g.112575328C\>Tchr2:g.112568874T\>Achr2:g.112568874T\>Achr2:g.112575328C\>Tchr2:g.112575328C\>Achr2:g.112575328C\>TcDNA position (NM_019014.5)c.3007C\>Tc.2046T\>Ac.2046T\>Ac.3007C\>Tc.3007C\>Ac.3007C\>TInheritanceDe novoDominantDominant (daughter of patient 2)De novoDominant (mosaic in father)De novoSexFemaleFemaleFemaleFemaleFemaleFemale**Prenatal growth** Gestational age30 + 6 WG38 WG29 + 4 WG34 + 4 WG40 WG41 + 6 WG Birth weight1120 g (8th percentile)3110 g (40th percentile)1620 g (80th percentile)1940 g (10th percentile)4200 g (93rd percentile)3230 g (15th percentile) Body length at birth37 cm (5th percentile)50 cm (65th percentile)ND44 cm (20th percentile)52.3 cm (80th percentile)51 cm (40th percentile) OFC27.5 cm (25th percentile)34.5 cm (60th percentile)ND31.5 cm (40th percentile)37.5 cm (90th percentile)34.5 cm (10th percentile)**Postnatal growth** Age at last examination27 months29 years22 months12 months20 years3 years Height82 cm (−1 SD)166 cm (+0.5 SD)78 cm (+0.5 SD)67,31 cm (−2.5 SD)Normal length103 cm (+3 SD) Weight8.4 kg (−3 SD)58 kg (+1 SD)8.84 kg (−1 SD)7.2 kg (−2 SD)Overweight15 kg (+1 SD) OFC47 cm (−1 SD)54 cm (−1 SD)47 cm (M)42.4 cm (−2 SD)ND49 cm (M)**Facial and extrafacial features** Downward slanting palpebral fissuresYYYY (asymmetric, left \> right)YY Malar hypoplasiaYYYYYY Conductive deafnessY (bilateral)NY (bilateral)Y (bilateral)Y (bilateral)Y (bilateral) Mandibular hypoplasiaMildNYYYY Atresia of external ear canalY (left) very narrow (right)NY (right)Y (bilateral)NY (bilateral) MicrotiaY (unilateral left)NY mildY (bilateral)NY (bilateral) Coloboma of the lower lidNNNY (right)YY Facial asymmetryNNNNYY (mild) Projection of scalp hair onto lateral cheekNNNNYN Nasogastric tube or gastrostomy in the neonatal periodYNYYYY Cleft palateNNNYYY Intubation or tracheostoma in the neonatal periodNNYYY, tracheostoma and canule for 6 yearsN Choanal stenosis/atresiaNNNNYY (unilateral right) Cardiac malformationNNNNNN Vertebrae malformationNNNNNN Renal malformationNNNNNN MicrocephalyNNNYNN Intellectual disabilityNNNNNN Anomaly of the limbsNNNNNN*cDNA* complementary DNA, *gDNA* genomic DNA, *M* mean, *ND* not determined, *OFC* occipital frontal circumference, *TCS* Treacher Collins syndrome, *WG* weeks of gestation.

Exome sequencing {#Sec4}
----------------

Nucleotide variations in the *POLR1B* gene (NM_019014.5) were all identified by using Agilent/Illumina exome sequencing. Sanger sequencing was used for sequence validation and segregation analyses of genetic variations identified in *POLR1B* (details are in the [Supplemental data](#MOESM1){ref-type="media"}).

3D modeling {#Sec5}
-----------

The 3D model of A135/Rpb2 was designed using homology modeling methods. The human variant sequences of *POLR1B* (p.\[Ser682Arg\], p.\[Arg1003Cys\], and p.\[Arg1003Ser\]) were searched in the online server ATOME2. This server uses Protein Data Bank (PDB) to find the best structure that fits the variant sequence. It introduces constraints, constructs a model, and refines the model. Our model is based on subchain B (A135/Rpb2) of the crystal structure of the *Saccharomyces cerevisiae* 14-subunit RNA polymerase (PDB 4C3I).^[@CR8]^ Human POLR1B and the yeast homolog have strong sequence identity, 44%, and probably share the same function in their complex. We did not use refinements with molecular dynamics for all other subchains because we wanted to assess only the possible perturbations of interactions due to those pathogenic variants.

Ethics statement {#Sec6}
----------------

Exome sequencing was performed as a clinical test (diagnosis not research) and thus institutional review board (IRB) approval was not required. All parents or legal guardians gave written informed consent for genetic diagnosis procedures according to the ethics committee of our institution. Informed consent for publication of images was obtained from five of six patients. The experiments performed on zebrafish were conducted as described previously^[@CR9]^ at the University of Montpellier according to European Union guidelines for handling laboratory animals and the Direction Sanitaire et Vétérinaire de l'Hérault and Comité d'Ethique under reference CEEA-LR-13007.

Zebrafish line and morpholino injections {#Sec7}
----------------------------------------

Experiments involved the AB zebrafish strain (ZIRC), transgenic *Tg*(*foxd3:GFP*)^[@CR10]^ and *Tg*(*sox10:GFP*)^[@CR11]^ to visualize NCCs, and transgenic *Tg*(*col2a:mcherry*)^[@CR12]^ to visualize cartilage. Embryos were obtained from pairs of adult fish by natural spawning and were raised at 28.5 °C in tank water. Embryos and larvae were staged as described.^[@CR13]^ For morpholino injections only embryos were used. To obtain enough eggs, 20 pairs of adult zebrafish were used for the breeding. When possible, we bred two different transgenic lines---(Tg\[Foxd3: GFP\] and Tg\[col2a:mcherry\]---to maximize information gathered from the experiments. For imaging and quantitative reverse transcription polymerase chain reaction (RT-qPCR) experiments, 20 embryos were injected per condition: 5 embryos were used for imaging and phenotypic screening, and 15 pooled to ensure enough RNA material for RT-qPCR analyses. Experiments were repeated six times to obtain biological replicates. No statistical methods were used to calculate sample size and no randomization method was used to determine how samples were allocated to experimental groups and processed. No blinding was done.

For *polr1b* (NM_200518.2) loss-of-function experiments, we used morpholino antisense oligonucleotides (Gene Tools, Philomath, USA) that bind to the region surrounding the translation start site of *polr1b* and block translation by steric hindrance (MO zPOLR1B-ATG, here called MO polr1b): 5' TTGCACCACTTGGAGAGATCCATGC 3'. Briefly, 2 nl MO polr1b (1 mM) or control morpholino (5' AATCACAAGCAGTGCAAGCATGATG 3', 1 mM) was injected in one cell--stage embryos by using a FemtoJet (Eppendorf).

Imaging and larvae manipulation {#Sec8}
-------------------------------

Larvae were anesthetized with 0.016% Tricaine (ethyl 3-aminobenzoate, Sigma Aldrich), mounted in 1% low melting temperature agarose in a FluoroDish and imaged by using confocal inverted microscopy (TCS SP5) with an MVX10 Olympus microscope equipped with an MVPLAPO 1× objective and XC50 camera.

**Terminal deoxynucleotidyl transferase dUTP nick end labeling** (TUNEL) experiment {#Sec9}
-----------------------------------------------------------------------------------

At 20 hours postfertilization (hpf), MO control- and MO polr1b-injected *Tg*(*sox10:GFP*) embryos were fixed with PFA 4% at 4 °C overnight, rinsed extensively with PBS-Tween (0.1%), and labeled for apoptosis detection by using the In Situ Cell Death Detection Kit, TMR red (Sigma), according to the manufacturer's instructions, then labeled with Hoechst. Embryos were mounted in 1% LMT agarose for confocal microscopy observation.

Molecular analyses in zebrafish {#Sec10}
-------------------------------

RNA from six groups of 15 each of MO control-- or MO polr1b--injected larvae at 24 hpf were collected by using the RNeasy Mini Kit (Qiagen). The M-MLV Reverse Transcriptase kit (Invitrogen) was used to synthesize complementary DNA (cDNA) for qRT-PCR with the primers for EF1a,^[@CR9]^ p53,^[@CR14]^ 18S rRNA, 5'-ETS, ITS1, ITS2,^[@CR15]^ and 5S.^[@CR16]^ SYBR Green I Master reaction mix (Roche) and Rotor-Gene Q (QIAGEN's real-time PCR cycler) were used for analysis of messenger RNA (mRNA) levels of genes. Quantitative PCR (qPCR) was performed with the protocol 10 minutes at 95 °C, denaturation 10 seconds at 95 °C, annealing 10 seconds at 64 °C, and elongation 20 seconds at 72 °C (45 cycles). The relative amount of mRNA was calculated by the 2^−∆Ct^ formula with EF1a as a reference.

Statistical analysis {#Sec11}
--------------------

Data were analyzed by using GraphPad Prism 6 software. Because of sample sizes (*n* \< 30), the unpaired Mann--Whitney nonparametric test was used to compare two groups. GraphPad does not report variances, and standard deviations are different between the groups that are being compared. *P* \< 0.05 was considered statistically significant.

Study approval {#Sec12}
--------------

Montpellier Hospital.

RESULTS {#Sec13}
=======

Exome sequencing identifies *POLR1B* as a novel candidate gene in TCS {#Sec14}
---------------------------------------------------------------------

Exome sequencing for patients 1, 2, and 3 revealed two potentially pathogenic single-nucleotide variations in *POLR1B* chromosome 2. In patient 1, we identified a missense variation, c.3007C\>T (NM_019014.5, p.\[Arg1003Cys\], chr2:g.112575328C\>T, hg38), in exon 15 of *POLR1B*. In individuals 2 and 3 (a girl and her mother), we identified a missense variation, c.2046T\>A \[NM_019014.5, p.(Ser682Arg), chr2:g.112568874T\>A, hg38\], in exon 12 of *POLR1B*. Both genetic variations were not found in the gnomAD database. In silico analysis predicted that the genetic variants were pathogenic (Supplementary Table [S1](#MOESM1){ref-type="media"}).

Via international collaboration, we found three additional individuals with TCS, and *POLR1B* pathogenic variants were identified by using exome and targeted sequencing. Table [1](#Tab1){ref-type="table"} summarizes the clinical and molecular data from these series. Pathogenic variants in *POLR1B* arise de novo or are inherited with a dominant pattern (Fig. [1a](#Fig1){ref-type="fig"}). One pathogenic variant (p.\[Arg1003Cys\], Fig. [1c](#Fig1){ref-type="fig"}) was common in three unrelated patients (patients 1, 4, and 6).Fig. 1***POLR1B*** **pathogenic variants in six patients with Treacher Collins syndrome (TCS).** (**a**) Pedigrees of five families with TCS. Solid symbols indicate affected family members (patients 1--6), open symbols indicate unaffected members, gray solid symbol (5^m^) indicates patient 5's father with mosaicism, and squares and circles indicate males and females, respectively. (**b**) Front and lateral view of patients from this series. (**c**) Representative electropherograms of pathogenic variants.

Pathogenic variants were confirmed by PCR with exons 12 and 15 specific primers for *POLR1B*. Sanger results are summarized in Fig. [1c](#Fig1){ref-type="fig"}. Analysis of parental blood by PCR and Sanger sequencing determined a de novo occurrence of the pathogenic variant for patients 1, 4, and 6. In the family of patients 2 and 3, the pathogenic variant was inherited from the affected mother. In addition, for patient 5 (c.3007C\>A, NM_019014.5, p.\[Arg1003Ser\], chr2:g.112575328C\>A, hg38), we identified mosaicism in DNA samples isolated from the father (identified as 5^m^ in Supplementary Fig. [S1](#MOESM1){ref-type="media"}), with approximately 16% variant alleles in blood samples (15 read with pathogenic variant and 81 without pathogenic variant). Also, a mosaic *POLR1B* pathogenic variant was detected in DNA isolated from saliva (Supplementary Fig. [S1](#MOESM1){ref-type="media"}). Of note, the father presented facial dysmorphism (slightly downslanted right eye, mild retrognathia, flat zygoma, big mouth, and thin eyelashes) but no hearing loss or coloboma.

All these data suggest that *POLR1B* haploinsufficiency was responsible for TCS in these five patients.

*POLR1B* pathogenic variants affect highly conserved amino acids and probably destabilize the bridge ɑ-helix {#Sec15}
------------------------------------------------------------------------------------------------------------

To investigate the potential impact of *POLR1B* pathogenic variants on the protein conformation, we performed a conformational analysis by using computational modeling of the crystal structure of the POLR1B protein. All three pathogenic variants affected highly conserved amino acids across species (Fig. [2a](#Fig2){ref-type="fig"}). Because the crystal structure of the human protein is not available, we generated a 3D structure prediction based on the crystal structure of the yeast homolog protein RPB2^[@CR8]^ by using an in silico analysis described in "Materials and Methods." Both wild-type residues Ser682 and Arg1003 are located in hydrogen bonds (Fig. [2b](#Fig2){ref-type="fig"}, left panel), which participate in the stabilization of the ɑ-helix Ser682-Gln724 of POLR1B. The amino acid substitution in the model suggested that the p.(Ser682Arg) pathogenic variant might disrupt the hydrogen bond between Ser682 of the POLR1B ɑ-helix and His967 of the POLR1A bridge helix Pro961-Leu1027 (Fig. [2b](#Fig2){ref-type="fig"}, right panel), which is a highly conserved sequence located in the catalytic domain of the protein.^[@CR8],[@CR17]^ Moreover, the p.(Arg1003Cys/Ser) pathogenic variants might destabilize the intramolecular hydrogen bond with the Gln724 residue.Fig. 2**In silico studies of consequences of** ***POLR1B*** **pathogenic variants.** (**a**) Uniprot alignment of POLR1B protein showing interspecies conservation of amino acids affected by pathogenic variants. Position of pathogenic variants and conservation across species are highlighted in bold. (**b**) Space fill model of POLR1B and its association with the POLR1A subunit of RNA polymerase around the variant residues. (Left) The wild-type (WT) structure: residue found pathologically modified in *Homo sapiens*. Distance compatible with hydrogen bond is indicated for Ser682-His967 and Glu724-Arg1003. (Right) p.(Ser682Arg) (S682R) and p.(Arg1003Cys) (R1003C) pathogenic variant model with Arg682, which clearly could hamper the ɑ-helix POLR1A wild-type position.

*Polr1b* expression profile and role during embryogenesis in zebrafish {#Sec16}
----------------------------------------------------------------------

To further define the role of POLR1B during the craniofacial formation process and identify the molecular mechanisms responsible for TCS, we used a zebrafish model. First, analysis of the *polr1b* expression profile during zebrafish embryogenesis by in situ hybridization revealed a dynamic pattern of expression (Thisse B, Thisse C. Fast release clones: a high-throughput expression analysis. 2004. ZFIN direct data submission. <https://zfin.org/ZDB-PUB-040907-1>). Indeed, although *polr1b* was ubiquitously expressed during gastrulation from 50% epiboly to bud stages, its expression became spatially restricted during segmentation in the retina, tectum, and somite. The tissue restriction of *polr1b* expression continued during pharyngula to become specific to the eye, tectum, posterior myotomes, and branchial arches. Second, to examine the role of *polr1b* during development of the craniofacial skeleton, we used the morpholino-mediated gene knockdown strategy. The phenotype examination of zebrafish morphants generated by using a morpholino antisense oligomer that creates a steric hindrance of the ATG start codon of *polr1b* (MO polr1b) revealed abnormal craniofacial development of zebrafish embryos from 20 hpf characterized by cranioskeletal hypoplasia, microtia, and microphthalmia (Fig. [3a](#Fig3){ref-type="fig"}). Also, compared with control morphants (MO control), 72-hpf *polr1b* morphants were proportionally smaller and exhibited cardiac edema, altered positioning of melanocytes along the anterior--posterior axis, and pectoral fin hypoplasia (Fig. [3b](#Fig3){ref-type="fig"}).Fig. 3***Polr1b*** **knockdown in zebrafish reduces neural crest cell (NCC) migration and causes severe craniofacial defects similar to Treacher Collins phenotype.** (**a**) At 20 hours postfertilization (hpf) (upper panels) and 48 hpf (lower panels), *polr1b* morphants present smaller heads, smaller eyes, and developmental delay (larger yolk sac) compared with controls (scale bars, upper panels = 400 µm, lower panels = 200 µm). (**b**) At 3 days postfertilization (dpf), *polr1b* morphants present smaller size as well as pigmentation defects (indicated by white arrows) compared with controls, and some morphants also present cardiovascular defects (large cardiac edema) and died at 4 dpf (data not shown). (**c**) *polr1b* morphants present altered NCC marker expression. At 30 hpf, injection of *Tg*(*sox10:GFP*) (upper panels) and *Tg*(*foxd3:GFP*) (lower panels) conferred NCC abnormalities in *polr1b* morphants compared with controls, in particular where branchial arches normally formed (white arrows, right panels), which indicates reduced migratory NCC population. (**d**) At 3 dpf, cranioskeletal structures were visualized by using *Tg*(*col2a:mCherry*). Compared with control morphants (MO Control), *polr1b* morphants (MO polr1b) lacked mandibular and branchial arches (1: mandibula, 3: branchial arches), and the otic vesicle was smaller (2). *polr1b* morphants show impaired pigmentation (pigments indicated by an asterisk) and cardiac edema (white arrow, upper right panel), which indicates that other NCC-derived tissues are affected. Scale bars = 200 µm. Five embryos were used in each condition and representative images of six experiments are shown.

We then focused on the development and behavior of NCCs, a migratory and multipotent cell population involved in craniofacial structures, in *polr1b* morphants. We injected MO *polr1b* in *Tg*(*sox10:GFP*) or *Tg*(*foxd3:GFP*) transgenic zebrafish embryos that expressed GFP in cells positive for master neural crest lineage markers such as *sox10* and *foxd3*, respectively. Compared with MO control heads, the smaller head observed in *polr1b* morphants was associated with decreased number of migrating *sox10*^*+*^ or *foxd3*^*+*^ NCCs in the head, in particular where branchial arches normally formed (Fig. [3c](#Fig3){ref-type="fig"}).

To further investigate the role of *polr1b* in NCC-derived craniofacial structures such as cartilaginous tissues, we injected MO *polr1b* in *Tg*(*col2:mCherry*) embryos with chondrocytes expressing mCherry and imaged them at three days postfertilization (dpf) (Fig. [3d](#Fig3){ref-type="fig"}). As revealed by image analysis and as compared with control morphants, *polr1b* morphants lacked mandibular and branchial arches, and the otic vesicle was smaller and misshapen (Fig. [3d](#Fig3){ref-type="fig"}). These results obtained with *polr1b* zebrafish morphants underline the phenotypic similarities with TCS patients showing *POLR1B* haploinsufficiency and suggest a new in vivo model for studying molecular mechanisms responsible for cranioskeletal defects in TCS.

Mechanisms responsible for decreased number of migrating NCCs in *polr1b*-deficient zebrafish {#Sec17}
---------------------------------------------------------------------------------------------

The production of ribosomes is highly conserved among species, which allows for deciphering the process in a tractable model system such as zebrafish. Ribosome biogenesis depends on RNA pol I and pol III activities that transcribe ribosomal DNA (rDNA) into 47S preribosomal RNA (pre-rRNA) and 5S rRNA, respectively (Supplementary Fig. [S2](#MOESM1){ref-type="media"}). Thus, we used qRT-PCR to analyze the expression profile of sequences of the 47S pre-rRNA including 18S rRNA, the internal transcribed spacer sequences 1 and 2 (ITS1, ITS2), and the 5' external transcribed spacer (5'-ETS) in the zebrafish morphants. Compared with control morphants, *polr1b* morphants showed significantly decreased levels of 5'ETS, ITS1, ITS2, and 18S. In contrast, the level of pol III--dependent 5S rRNA was similar in both morphants (Fig. [4a](#Fig4){ref-type="fig"}). Hence, *polr1b* knockdown did not affect pol III function, but it specifically altered pol I activity and thus the generation of 47S pre-rRNA during ribosome biogenesis.Fig. 4***Polr1b*** **knockdown in zebrafish alters RNA polymerase I (pol I)--mediated ribosome biogenesis in neural crest cell (NCC) precursors.** (**a**) Ribosomal RNA (rRNA) transcript expression profile in control and polr1b morphants by quantitative reverse transcription polymerase chain reaction (qRT-PCR) normalized to EF1a level. 5'ETS, ITS1, ITS2, and 18S depend on RNA pol I activity, whereas 5S is RNA pol III--dependent. (**b**--**e**) Confocal images of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) labeling (in red) of 20 hpf *Tg*(*sox10:GFP*) embryos (lateral views in (**b**,**d**), dorsal views in (**c**,**e**)). Imaging of apoptotic cells stained with TUNEL in polr1b and control morphants (dorsal part indicated by white arrows in (**d**,**e**)). Scale bar: 100 µm. (**f**) Quantification of TUNEL-positive cells in MO control and MO polr1b (*n* = 10 zebrafish larvae in MO control and *n* = 11 zebrafish larvae in MO polr1b). (**g**) Quantification of p53 messenger RNA (mRNA) level in MO control and MO polr1b (*n* = 6 groups of 15 pooled zebrafish larvae at 24 hpf). Data are mean ± SEM. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001 by one-tailed unpaired Mann--Whitney nonparametric test.

We next used the zebrafish model to further understand how *polr1b* deficiency and the subsequent altered pol I activity might affect the generation or migration of NCCs. Given the phenotype of *polr1b* morphants and that pol I is of main importance in regulating ribosome biosynthesis and protein translation, we hypothesized that POLR1B, a subunit of pol I, might play a key role in NCC viability. To detect and quantify apoptosis in zebrafish morphants, we used TUNEL assay. Confocal imaging of 20-hfp *Tg*(*sox10:GFP*) embryos revealed a higher apoptotic rate in *polr1b* morphants than controls (Fig. [4b--e](#Fig4){ref-type="fig"}). The massive apoptosis observed in *polr1b* morphants was mainly in the dorsal part of the embryos (Fig. [4d, e](#Fig4){ref-type="fig"}). Of note, *sox10*^*+*^ NCCs were TUNEL-negative in both *polr1b* morphants and controls, but massive cellular apoptosis was observed in the neuroepithelium of *polr1b* morphants (Fig. [4b--e](#Fig4){ref-type="fig"}). Therefore, the increased number of apoptotic cells in *polr1b* morphants did not concern NCCs that emigrate from the neural crest but rather cells of the neuroepithelium fated to differentiate into NCCs. Hence, we highlight for the first time that *polr1b* exhibits a nonredundant, spatiotemporal restricted function during gastrulation, which is critical for ribosome biogenesis in NCC precursors and thus their viability before NCC induction and delamination. Finally, we investigated whether the altered ribosome biogenesis caused by *polr1b* deficiency and the subsequent massive apoptosis observed in *polr1b* morphants could be associated with the level of p53 transcript. qRT-PCR revealed significantly higher p53 expression in 24-hpf *polr1b* morphants than controls at the same developmental stage (Fig. [4g](#Fig4){ref-type="fig"}).

DISCUSSION {#Sec18}
==========

TCS is a rare craniofacial disorder characterized by facial bone hypoplasia that results from extensive apoptosis of neuroepithelial progenitors and subsequent abnormal migration of NCCs.^[@CR18]^ Variants in three genes (*TCOF1*, *POLR1C*, and *POLR1D*) have been found responsible for TCS but fail to explain all cases. In the present study, we report six TCS patients with bilateral and symmetrical malar and mandibular hypoplasia with associated facial abnormalities (microtia, coloboma, and downslanting palpebral fissures) and pathogenic variants in a novel causative gene, *POLR1B*. Patients with *POLR1B* pathogenic variants have craniofacial features similar to TCS patients with pathogenic variants in the other genes, although the number of reported patients is limited. We also show that, similar to TCS patients with the *POLR1B* pathogenic variant, *polr1b* knockdown in zebrafish caused severe craniofacial defects. Our results support the implication of *POLR1B* pathogenic variants in newly identified TCS patients.

TCS has been referred to as a heterogeneous genetic disorder caused by pathogenic variants in three different genes, which are all involved in ribosome biogenesis. Indeed, treacle, the protein encoded by *TCOF1*, is involved in ribosomal DNA gene transcription by interacting with the upstream binding factor,^[@CR19]^ which is directly involved in initiating transcription of ribosomal DNA by RNA pol I.^[@CR20]^ RNA pol I is responsible for the synthesis of the 47S/45S pre-rRNA, which is cleaved post-transcriptionally into 18S, 5.8S, and 28S RNA molecules by small nucleolar RNAs.^[@CR21]^ The reduction in 2'-O-methylation at nucleotide 463C of 18S rRNA observed in *Tcof1*^+/−^ mice embryos suggests that *Tcof1* might link RNA pol I--catalyzed transcription and post-transcriptional modification of pre-rRNA.^[@CR22]^ Craniofacial structures including maxilla and mandible bones derive from the first pharyngeal arch, themselves originating from NCCs that emerge from the neuroepithelium. In mice, treacle is expressed at the edges of the neural folds and also in the developing branchial arches.^[@CR18]^ Mouse embryos with *Tcof1* haploinsufficiency show significantly reduced preribosome RNA levels as well as decreased mature ribosome number in the neuroepithelium and NCCs.^[@CR19]^ The other genes responsible for TCS, namely *POLR1C* and *POLR1D*,^[@CR5]^ encode subunits that belong to the 14-subunit RNA pol I protein.^[@CR23]^ Like *TCOF1*, the genes *POLR1C* and *POLR1D* disturb the biogenesis of ribosomes as well as NCC generation and survival, causing TCS when presenting pathogenic variation.^[@CR3]^ Additionally, *POLR1A* encoding for the largest subunit of RNA pol I was found responsible for an acrofacial dysostosis named acrofacial dysostosis Cincinnati type.^[@CR14]^

Our study expands on the genotypic and phenotypic heterogeneity of congenital acrofacial disorders resulting from ribosome biogenesis disruption. In line with previous reports, we show that *polr1b* knockdown in zebrafish was associated with a deficit of rRNA transcripts specifically dependent on RNA pol I. Also, this *polr1b* knockdown induced massive apoptosis in the neuroepithelium at the NCC formation stage, which was accompanied by increased p53 expression. Similarly, the zebrafish *polr1a* variant shows deficiencies in the biogenesis of ribosomes leading to extended death in the neuroepithelium and subsequent cranioskeletal malformation mimicking TCS.^[@CR14]^ In addition, zebrafish studies demonstrated that pathogenic variants in *polr1c* and *polr1d* lead to craniofacial features mimicking defects observed in TCS.^[@CR3]^ Impaired ribosome biogenesis can cause activation of p53, leading to cell cycle arrest.^[@CR24]^ In a study using the *Tcof1* variant mouse, inhibition of p53 prevented TCS.^[@CR25]^ From these studies and our data, we propose that in TCS patients with pathogenic variants in *POLR1B*, massive p53-dependent apoptosis of cells within the neuroepithelium is responsible for the poor number of migrating NCCs and the cranioskeletal malformations.

Considering that haploinsufficiency of *Tcof1*, or other genes belonging to the RNA pol I macromolecule, is sufficient to lead to neuroepithelium and NCC death during development, TCS could be explained by increased sensitivity of the neuroepithelium and NCCs to cell stress (here ribosome biogenesis deficiency) at this specific time of development. During embryogenesis in zebrafish, the expression of *polr1b* is ubiquitous at early stages and becomes progressively restricted. At the pharyngula stage, *polr1b* expression is restricted to pharyngeal arches, which suggests a role for *polr1b* in these NCC derivatives. However, in line with *Tcof1* studies in mice^[@CR19],[@CR25]^ and studies of RNA pol I subunits^[@CR3],[@CR14]^ in zebrafish, we showed that NCC apoptosis occurs in the neural tube and not in migrating NCCs or in NCC derivatives in which we observed this restricted expression of *polr1b*. Although the expression patterns of the different RNA pol I subunits in tissues originating from the neural crest remain unexplored during human embryo development, one interesting research line for future studies would be to determine a possible association with extended neuroepithelium cell death in TCS.

Finally, our conformational analysis based on the crystal structure of the homologous yeast protein showed that all three pathogenic variants affected amino acid residues involved in hydrogen bond interactions with the ɑ-helix Ser682-Gln724 of POLR1B. Importantly, the pathogenic variant affecting Ser682 might introduce a steric constraint on the helix position and directly affect the interaction between the POLR1B ɑ-helix and the N-terminal portion of the bridge helix of POLR1A. The bridge helix domain is a central component of the catalytic site of all cellular RNA polymerases (RNAPs). It coordinates the movement of several other domains during catalysis and is involved in all known functions of RNAPs.^[@CR17]^ High-throughput mutagenesis studies of the *Methanocaldococcus jannaschii* bridge helix domain showed that pathogenic variants affecting this domain, and in particular the molecular hinge region in the N-terminal portion of the bridge helix, severely reduced RNAP enzymatic activity.^[@CR26]^ In particular, every pathogenic variant on His808, homolog of His967 in POLR1A, induces a strong decrease in catalytic activity. We hypothesized that the p.(Ser682Arg) pathogenic variant could produce the same loss of function. Both pathogenic variants affecting the amino acid residue at position 1003 might disrupt the hydrogen intramolecular interaction with the ɑ-helix Ser682-Gln724 of POLR1B and indirectly destabilize the bridge helix of POLR1A, thus similarly reducing RNAP activity of the *H. sapiens* protein.

In conclusion, TCS so far belongs to the largest group of diseases named ribosomopathies (e.g., Diamond--Blackfan syndrome),^[@CR27]^ and our present work adds *POLR1B* to the list of genes (*TCOF1*, *POLR1A*, *POLR1C*, and *POLR1D)* already known to be crucial for ribosome biogenesis and NCC survival. The proportion of TCS attributed to pathogenic variants in *TCOF1*, *POLR1C*, and *POLR1D* is 63--93%, 6%, and 1.2%, respectively.^[@CR28]^ Because the *POLR1B* pathogenic variants we describe diagnoses 1.3% of the 4% of individuals with typical clinical signs of TCS but without a molecular diagnosis, our study has important consequences for genetic diagnosis of TCS.
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